Have questions for our experts or want more information?
Contact Us Today
Webinar Overview
The industry is at a crossroads. As antibody-based therapeutics grow more complex, the traditional development model is no longer enough. Regulatory expectations are shifting, and so must your strategy.
This webinar challenges conventional thinking and introduces a human-relevant, animal-light approach to antibody development. Discover how new approach methodologies (NAMs), including organoids, primary tissue models, cell microarrays, and AI-powered prediction tools, can transform your discovery to IND continuum to improve translational outcomes.
View this webinar to learn about:
- How integrated NAMs are being used to de-risk antibody programs and accelerate timelines
- Cutting months off lead-to-IND without compromising safety or scientific rigor
- Building regulatory-ready data packages that support first-in-human dose selection
- Why aligning with the FDA’s evolving guidance on NAMs is no longer optional, it’s strategic
Whether you’re designing a first-in-human study or refining your safety cascade, this webinar will show you how to lead with innovation because every moment matters.
Webinar Presenters
Namrata Jayanth, PhD
Research Leader, Biotherapeutics
Charles River
Jan Iyer, PhD
Director, AI/ML Platform Product
Absci